Bristol-Myers Squibb Company (FRA:BRM)
40.67
-0.06 (-0.16%)
Last updated: Jul 30, 2025
FRA:BRM Revenue
Bristol-Myers Squibb Company had revenue of $12.27B USD in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to $47.70B, up 2.57% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.70B
Revenue Growth
+2.57%
P/S Ratio
1.92
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
77.97B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Bristol-Myers Squibb Company News
- 7 days ago - Bristol Myers Squibb taps Cristian Massacesi as CMO - Seeking Alpha
- 7 days ago - Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development - Wallstreet:Online
- 9 days ago - Peering Into Bristol-Myers Squibb's Recent Short Interest - Benzinga
- 10 days ago - A Look Into Bristol-Myers Squibb Inc's Price Over Earnings - Benzinga
- 10 days ago - FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks - Benzinga
- 11 days ago - Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 11 days ago - Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally - Benzinga
- 14 days ago - Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer - Seeking Alpha